Novo Nordisk for Osteoarthritis

News

Novo Nordisk ousts CEO

Novo Nordisk announces CEO transition as share price slips

After nearly tripling the company’s value, CEO Lars Fruergaard Jørgensen is preparing to exit amid boardroom shifts. Novo Nordisk announced Friday that it would part ways with its longtime CEO, who steered the company into an unprecedented boom time for weight-loss drugs.

· 4d · on MSN

Novo Nordisk CEO will step down amid falling share price and 'recent market challenges'

· 4d · on MSN

Analysis-Novo Nordisk Should Look to the US for Its Next CEO, Analysts Say

23h

Novo Nordisk and US biotech company team up to create obesity pills

Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, ...

Healthline5d

FDA Accepts Novo Nordisk’s Application for Oral Wegovy: 5 Things to Know

Federal regulators have accepted Novo Nordisk’s application to produce a pill version of its injectable weight-loss ...

Yahoo Finance7d

Novo Nordisk A/S: Septerna and Novo Nordisk to collaborate on oral small molecule medicines for obesity and other cardiometabolic diseases

“Novo Nordisk has a rich history of innovation in obesity and diabetes. We are building on our scientific leadership in this space and developing a broad pipeline across various targets and ...

Reuters5d

Novo Nordisk ousts CEO after falling behind in weight loss market

Under Jorgensen's leadership, Novo Nordisk became a world leader in the lucrative weight-loss drug market, with sky-rocketing sales of its Wegovy and Ozempic treatments. Sign up here. "The changes ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results